Ads
related to: keytruda cost per year- Treatment Information
Learn More About What To Expect
When Taking ADSTILADRIN®.
- Support & Resources
View Patient Assistance, Coverage
Support, & Other Valuable Resources
- Learn About ADSTILADRIN®
Discover Important Product
And Treatment Information.
- What Is ADSTILADRIN®?
Learn About Treatment With
ADSTILADRIN® And How It Works.
- Treatment Information
Search results
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 1 month agoMerck MRK reported adjusted earnings of $2.07 per share for first-quarter 2024, beating the Zacks...
Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales
Zacks via Yahoo Finance· 7 months agoMerck MRK reported adjusted earnings of $2.13 per share for third-quarter 2023, beating the Zacks...
Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot
Reuters via Yahoo News· 1 year agoU.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy...
Merck (MRK) Beats on Q4 Earnings & Sales, 2023 View Disappoints
Zacks via Yahoo Finance· 1 year agoMerck MRK reported fourth-quarter 2022 adjusted earnings of $1.62 per share, which beat the Zacks...
Merck (MRK) Beats on Q3 Earnings & Revenues, Ups 2022 View
Zacks via Yahoo Finance· 2 years agoMerck & Co., Inc. MRK reported third-quarter 2022 adjusted earnings of $1.85 per share, beating the...
Why Is Merck (MRK) Up 4.3% Since Last Earnings Report?
Zacks via Yahoo Finance· 9 months agoIt has been about a month since the last earnings report for Merck (MRK). Shares have added about...
Personalized cancer vaccine results are a 'home run': Moderna CEO
Yahoo Finance via AOL· 1 year agoPreliminary results from a personalized cancer vaccine jointly studied by Moderna (MRNA) and Merck...
Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales
Zacks via Yahoo Finance· 1 year agoMirati Therapeutics MRTX reported a loss of $3.51 per share for fourth-quarter 2022, narrower than...
Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View
Zacks via Yahoo Finance· 4 months agoMerck MRK reported adjusted earnings of 3 cents per share in fourth-quarter 2023, wider than the...
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 1 month agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Ad
related to: keytruda cost per year